A Randomized, Naturalistic, Parallel-Group Study for the Long-Term Treatment of Panic Disorder With Clonazepam or Paroxetine
Authors:
- Antonio E. NardiANAntonio E. Nardi
- Rafael C. FreireRFRafael C. Freire
- Marina D. MochcovitchMMMarina D. Mochcovitch
- Roman AmreinRARoman Amrein
- Michelle N. LevitanMLMichelle N. Levitan
- Anna L. KingAKAnna L. King
- Alexandre M. ValençaAVAlexandre M. Valença
- André B. VerasAVAndré B. Veras
- Flávia PaesFPFlávia Paes
- Aline SardinhaASAline Sardinha
- Isabella NascimentoINIsabella Nascimento
- Valfrido L. De-Melo-NetoVDValfrido L. De-Melo-Neto
- 1 February 2012
- journal article
- research article
- Published by Wolters Kluwer Health in Journal of Clinical Psychopharmacology
- Vol. 32 (1) , 120-126
Abstract
This long-term extension of an 8-week randomized, naturalistic study in patients with panic disorder with or without agoraphobia compared the efficacy and safety of clonazepam (n = 47) and paroxetine (n = 37) over a 3-year total treatment duration. Target doses for all patients were 2 mg/d clonazepam and 40 mg/d paroxetine (both taken at bedtime). This study reports data from the long-term period (34 months), following the initial 8-week treatment phase. Thus, total treatment duration was 36 months. Patients with a good primary outcome during acute treatment continued monotherapy with clonazepam or paroxetine, but patients with partial primary treatment success were switched to the combination therapy. At initiation of the long-term study, the mean doses of clonazepam and paroxetine were 1.9 (SD, 0.30) and 38.4 (SD, 3.74) mg/d, respectively. These doses were maintained until month 36 (clonazepam 1.9 [SD, 0.29] mg/d and paroxetine 38.2 [SD, 3.87] mg/d). Long-term treatment with clonazepam led to a small but significantly better Clinical Global Impression (CGI)-Improvement rating than treatment with paroxetine (mean difference: CGI-Severity scale -3.48 vs -3.24, respectively, P = 0.02; CGI-Improvement scale 1.06 vs 1.11, respectively, P = 0.04). Both treatments similarly reduced the number of panic attacks and severity of anxiety. Patients treated with clonazepam had significantly fewer adverse events than those treated with paroxetine (28.9% vs 70.6%, P < 0.001). The efficacy of clonazepam and paroxetine for the treatment of panic disorder was maintained over the long-term course. There was a significant advantage with clonazepam over paroxetine with respect to the frequency and nature of adverse events.Keywords
This publication has 23 references indexed in Scilit:
- Randomized, Open Naturalistic, Acute Treatment of Panic Disorder With Clonazepam or ParoxetineJournal of Clinical Psychopharmacology, 2011
- The Epidemiology of Panic Attacks, Panic Disorder, and Agoraphobia in the National Comorbidity Survey ReplicationArchives of General Psychiatry, 2006
- Paroxetine Response and Tolerability Among Ethnic Minority Patients With Mood or Anxiety DisordersThe Journal of Clinical Psychiatry, 2005
- The epidemiology of panic disorder and agoraphobia in EuropeEuropean Neuropsychopharmacology, 2005
- The Role of High-Potency Benzodiazepines in the Treatment of Panic DisorderThe Primary Care Companion For CNS Disorders, 2005
- Paroxetine in panic disorder: clinical management and long-term follow-upExpert Review of Neurotherapeutics, 2004
- A 15-year follow-up study of patients with panic disorderEuropean Psychiatry, 2003
- Double-blind clonazepam vs placebo in panic disorder treatmentArquivos de Neuro-Psiquiatria, 2000
- The Long-Term Course of Panic Disorder and Its PredictorsJournal of Clinical Psychopharmacology, 1998
- Long‐term evaluation of paroxetine, clomipramine and placebo in panic disorderActa Psychiatrica Scandinavica, 1997